Cancer is emerging as a major public health problem in India. Cancer is life threatening because malignant tumors usually grow and spread across different organs in asymptomatic healthy individuals over many years.

All cells normally grow and divide (multiply) to replace old cells and thus keep the body healthy. A cell turns malignant and spreads across the body uncontrollably if undetected.

Symptoms don’t usually show up till late stages of cancer where treatment becomes difficult or impossible.

PanTum® Detect is a “fully body” screening blood test suited for “Pan Tumor” screening of an asymptomatic healthy individual.

The screening blood test is “universal” as it detects signals of silently growing malignant tumors covering all organs of the human body and consequently covering all cancer types.

The blood test is ideally suited for “pan-tumor” innovative screening of individuals with an intact immune response with regards to scavenging function of circulating macrophages (immune cells).

The test is used to identify “individuals” with presence of silently growing precancerous and/or malignant tumors:

1. Regular full body screening of asymptomatic healthy individuals to “filter” screened candidates for presence of silently growing pre-cancerous (benign) and malignant tumor growth independent of tumor entity.

2. Individuals under medical management of key tumor detection specialties (Neurologist, Ear Nose Throat (ENT), Dentist, Obstetrics and Gynecologist, Pulmonologist, Gastroenterologist, Urologist, Gen Physicians/IM, Nephrologist, Hepatologist, Pancreatologist, endocrinologist, Dermatologists etc etc) can benefit from a full body screening for silently growing precancerous and/or malignant tumors, independent of tumor entity.

3. The tumor detection medical specialists use the results of PanTum Detect blood test to correlate with other diagnostic test results and associated disease related symptoms.

Medidect India is bringing this revolutionary German solution to outsmart cancer and remove it from the “silent killer” list for benefit of all residents of India.

PanTum® Detect blood test uses the proprietary German EDIM technology that leverages our innate immune system to distinguish between silently growing pre-cancerous (benign) and malignant tumor growth independent of tumor entity.

Macrophages are a type of white blood cells that function as a component of our innate immune system. They are differentiated monocytes that turn into macrophages to fight invading germs (viruses, bacteria, fungi, protozoa etc.) that enter the human body.
Macrophage cells surround the invading germ, ingest, and kill it with enzymes within the cell. Macrophages “eat the tumor cell” as part of its scavenging function and thus play a crucial role in defending humans from the invading dangerous tumor cells.

PanTum® Detect uses a proprietary EDIM (Epitope Detection in Monocytes) Technology developed by Zyagnum AG, a German bio-tech company, for intracellular detection of “pan- tumor” enzyme biomarkers DNaseX (Apo10) & TKTL1 in macrophages.

The joint use of DNaseX (Apo10) & TKTL1 distinguishes between benign/ pre-cancerous and malignant tumor growth, independent of tumor entity. While DNaseX (Apo10) can be found in all pre-cancerous (benign) and malignant tumor cells, TKTL1 is detectable in all malignant/cancer cells. The expression of TKTL1 initiates diverse stages of malignancy progression and provides earliest possible indication of a malignant tumor growth.

PanTum® Detect has an IVD CE certified and Indian study validated specificity of 99% (true negatives) and sensitivity of 97.5% (true positives).

As demonstrated by the IVD CE clinical study and validated by the study on Indian population conducted for the Indian Drugs regulator, statistically:

• 1 in 100 candidates screened will receive a false positive result i.e they don’t have any disease but test positive.
• 2.5 in 100 candidates with the disease will receive a false negative result i.e., they do have the disease but test negative.

Individuals who want to undergo testing with PanTum® Detect must be in a healthy state to ensure highest blood sample quality.

This is because PanTum® Detect uses our innate immune system to screen asymptomatic healthy individuals with silently growing dangerous tumors. It is thus a necessary condition that the screening candidate has an intact and robust immune system, or more specifically that the individual’s immune system is not influenced by medication or treatment or illness.

PanTum® Detect is not suitable for individuals with a compromised immune system in terms of the functioning of macrophages.

2 hours fasting after last meal is required at the time of sample collection.

Cancer-Scan Program is an integrated multi-cancer screening concept that combines pretesting with PanTum^® Detect and follow up cancer diagnostics only for those individuals that test positive with PanTum^® Detect.

Leveraging available pathology and imaging techniques for multi- cancer screening is now possible by pre-testing with PanTum^® Detect. Available appropriate imaging techniques can potentially be used to detect dangerous tumors at an early, symptomless stage for healthy individuals. However, these imaging techniques have high cost, limited availability and pose a risk of radiation and invasive exposure for individuals, thus, not used on healthy individuals without suspicion of a dangerous tumor.

Combined with pretesting with PanTum^® Detect, only those “screened” candidates testing positive with PanTum^® Detect need follow-up cancer diagnostics to locate the spread of the malignant tumor growth.

Asymptomatic healthy individuals will benefit from being pretested with PanTum^® Detect blood test:

• Candidates screened positive for malignancy (TKTL1 expression) and confirmed with pre-malignant tumors as evidenced by the standard pathology and Imaging diagnostic pathway can be diagnostically and medically monitored for prevention of onset of cancer.
• Candidates screened positive for malignancy (TKTL1 expression) and confirmed with malignant tumors that may have already metastasized (spread to other organs of the human body) enter the treatment cycle far earlier than the onset of symptoms which normally happens only in late stages.
• Candidates screened negative at regular intervals benefit from protection from late stage cancers and consequently capping their risk of developing cancer to early stages where cure with much higher survival rates is possible.

Benefits:

• PanTum® Detect has a validated high sensitivity of 97.5% (true positives) and specificity of 99% (true negatives).
• Available cancer diagnostic pathology and imaging solutions can be used more efficiently and effectively by pre testing with PanTum® Detect blood test.
• Only those screened candidates who test positive with PanTum® Detect are exposed to follow up cancer pathology and imaging diagnostics.
• Regular screening increases the chance of detecting a silently growing tumor in an early stage.
• Regularly screened candidates are protected from life threatening late-stage cancers.
• Regular screening will lead to saving lives and elimination of financial toxicity associated with late stage cancer treatment.

Limitations:

• PanTum^® Detect is not suitable for individuals with a compromised human immune system that has a negative effect on circulating macrophage numbers.
• No screening test provides a result that is 100% accurate or
  • Statistically, 1 in 100 candidates screened will receive a false positive result (they don’t have the disease but test positive).
  • Statistically 5 in 100 candidates with disease will receive false negative result (they do have the disease but test negative).
• False results are a psychological strain for individuals that get screened with PanTum^® Detect.

No, the test does not show the type, spread, or location of cancer. It is a test for full body screening of healthy individuals to filter individuals that are “at risk” of developing cancer, rather than for detecting individual organ specific cancer types. 

PanTum® Detect is a simple blood test for “pan-tumor” screening of healthy individuals for presence of silently growing dangerous tumors.

Only those screened candidates who test positive with PanTum® Detect are exposed to available follow up standardized pathology and imaging cancer diagnostics for location and spread of malignant tumors (cancer).

If your test is found to be positive, an empanelled doctor guides the process of follow up examinations including referral to an oncologist for treatment.

Pre-tested candidates screened positive for malignancy undergo targeted pathology & imaging to confirm the location and spread of malignant tumors:

• Candidates confirmed with pre-malignant tumors as evidenced by the standard pathology and Imaging diagnostic pathway can be diagnostically and medically monitored for possible prevention of onset of cancer.
• Candidates confirmed with malignant tumors that may have already metastasized (spread to other organs of the human body) enter the treatment cycle far earlier than the onset of symptoms which normally happens only in late stages of cancer.

Our integrated multi cancer screening concept, Cancer-Scan has the advantage that many more people can be screened for early detection of multiple cancers as it becomes more efficient and affordable in combination with pretesting with PanTum^® Detect.

Cancer-Scan Program defines standard cancer diagnostics protocols for targeted pathology and imaging interventions for location and spread of malignant tumors.

Our empanelled doctors coordinate and guide the process of targeted cancer diagnostics as opposed to the “excessive” testing necessitated on the onset of symptoms and warning signs typically associated with late-stage cancer detection.

Targeted cancer diagnostic protocols have the advantage of being more efficient and affordable in combination with pretesting with PanTum® Detect blood test.